Tesamorelin

Published · Researched 2026-09-21

Research file — dated 2026-09-20. Research documentation only; not medical advice.

Overview — maker/originator, what it is, current 2026 status

Tesamorelin is a synthetic GHRH (growth hormone-releasing factor) analog developed by Theratechnologies (Montreal). It is the only FDA-approved GHRH analog in 2026: approved November 2010 as Egrifta for reduction of excess visceral abdominal fat in HIV-infected adults with lipodystrophy (2 mg once daily). The brand was renamed Egrifta SV, and a third formulation, Egrifta WR, received FDA approval in March 2025 for the same indication (Louisiana Blue medical policy, current effective 02/01/2026). Phase III trials (816 patients) showed ~15–17% visceral adipose tissue reduction by CT scan. In the peptide community it is simultaneously the most clinically credentialed secretagogue and a heavily used gray-market fat-loss peptide — most community use is compounded/gray-market tesamorelin, not Egrifta.

Sources: https://www.poz.com/article/hiv-egrifta-tesamorelin-lipodystrophy-19804-4221; https://www.lablue.com/-/media/Medical Policies/2020/08/03/17/36/tesamorelinEgrifta.pdf (policy current 02/01/2026); https://peptiq.io/peptides/tesamorelin (all accessed 2026-09-20)

Social standing — platform pulse

  • Instagram: One of the most discussed GH peptides of 2026. A tattooed educator's May 2026 cycling video argues tesamorelin (unlike ipamorelin) needs no cycling because, per studies he cites, it maintained stable IGF-1 over 52 weeks of daily use without desensitization (creator-cited — UNVERIFIED, do not state as fact). A bearded creator ranks tesamorelin the "gold standard" for visceral fat, citing real studies and FDA approval, while noting the reputation comes from trial design (CT-measured VAT in HIV patients), not a unique mechanism — head-to-head GHRH comparisons were never done. Nick Barrow's Sept 2026 ranking places tesamorelin #2 for visceral fat. Josh Holyfield's Sept 2026 carousel argues tesamorelin is labeled the "visceral fat peptide" only because its manufacturer pursued the HIV-lipodystrophy indication, and that CJC-1295 (same pituitary GHRH receptors, same pathway) would likely show similar results at lower cost. Dr. Jason Pencek's Aug 2026 infographic series contrasts tesamorelin's physiologic GHRH-receptor pathway against higher-GH-exposure alternatives ("stronger is not always smarter"). Comments across posts discuss stacking with HGH, flushing side effects, bloodwork, and cost ($13–$180 per 10 mg reported in one comment thread — UNVERIFIED range).
  • Facebook: Dr. Jason Pencek's Sept 2026 "Growth Hormone Peptide List" reel names tesamorelin among seven; comment section is dominated by vendor spam (LPpeptide, Napsgear), with genuine threads on cost-effectiveness, muscle-growth ranking, and insulin-resistance concerns.
  • Threads: User mrwhite09 calls tesamorelin "one of my most important nighttime peptides," taken before bed. User diario.dimagrire asks the community whether anyone has actually seen a change in fat percentage on it.
  • Group consensus: Tesamorelin = the fat-loss/visceral-fat GHRH with real FDA credentials and real trial data; respected but expensive; an active debate runs over whether it is meaningfully different from cheaper CJC-1295 (same receptor, same pathway — the difference is trial endpoints and cost).
  • Viral moments: The May 2026 "cycle ipamorelin, not tesamorelin" video and the Sept 2026 Holyfield "visceral fat is a labeling artifact" carousel are the two highest-engagement tesamorelin-native posts.
  • Main praise: Only FDA-approved GHRH analog; real Phase III VAT data (~15–17% reduction); stable IGF-1 over long use per creator-cited studies; GHRH pathway (no ghrelin-receptor cortisol/prolactin baggage); "gold standard" for visceral fat.
  • Main complaints: Price — Egrifta is ~$10k+/mo retail (see Pricing); users report flushing/warmth, injection-site reactions, fluid retention/carpal-tunnel-like swelling at higher doses; blood-glucose elevation flagged for diabetics/prediabetics; heavy vendor spam (Telegram/Napsgear) pollutes every comment section.
  • Quotes: Threads user mrwhite09: "one of my most important nighttime peptides."

Social validation — Tier 1

Tier 1 — Instagram (dense educator/owner content, May–Sept 2026), Facebook (Pencek reel + comment discussion), Threads (mrwhite09, diario.dimagrire), plus mainstream press (Scientific American, Sept 2026).

Named sources:

  • https://peptiq.io/peptides/tesamorelin — PeptIQ tracker; proves FDA-approved status, 2 mg daily Phase III dosing, community-reported side effects (flushing, water retention, carpal-tunnel symptoms, glucose elevation).
  • Instagram May 2026 cycling video (tattooed educator) — proves the no-desensitization/52-week claim circulating in the community (UNVERIFIED).
  • Instagram Sept 2026 Holyfield carousel (entry 82) — proves the "same receptor as CJC-1295, labeling artifact" counter-narrative.
  • Threads mrwhite09 post — proves real-user nighttime-use framing.
  • https://www.facebook.com/reel/1254886360104399/ — Dr. Pencek GH peptide list reel; proves tesamorelin's place in clinical-education content and the spam problem around it.

Key specs table

Spec Detail
Class Synthetic GHRH (GRF) analog — modified 44-aa human GHRH with N-terminal trans-3-hexenoyl group
Mechanism Binds pituitary GHRH receptors → pulsatile endogenous GH synthesis/release; more physiologic than rhGH; does not act on ghrelin receptors
Half-life Short (native-like GHRH kinetics; exact figure UNVERIFIED)
Route Subcutaneous injection
Approved dosing Egrifta: 2 mg (two 1 mg vials) SC once daily; Egrifta SV: 1.4 mg (0.35 mL) per current IFU (source: prescriberpoint.com, 2026)
Community-reported dosing 1–2 mg daily, often at night before bed (community ranges; labeled as such)
Molecular weight / CAS MW ~5,136 Da; CAS 218949-48-5 — UNVERIFIED, not confirmed today
Trial efficacy ~15–17% VAT reduction by CT at 26 weeks vs placebo (Phase III, n=816; source: POZ/EMD Serono reporting)

Pricing

  • Approved-drug price: Egrifta SV retail ~$10,547–$11,707/month via discount coupons (WellRx, September 2026 data, crawled 2026-09-20: https://www.wellrx.com/egrifta-sv/coupon/); drugs.com lists ~$7,486 for a 30-day kit (https://www.drugs.com/price-guide/egrifta). Manufacturer patient support (Thera Patient Support Program) may reduce copay for eligible commercially insured patients.
  • Research-chem / gray-market price: Community comment threads report wide ranges (one thread: $13–$180 per 10 mg — UNVERIFIED, single thread, 2026); typical vial prices not collected 2026-09-20 — UNVERIFIED.
  • Compounded/clinic price: Telehealth/clinic tesamorelin programs exist; exact 2026 prices not collected — UNVERIFIED.
  • Marketplace range: No listings observed 2026-09-20.

What's included / what's needed

  • Egrifta SV kit: 30 × 2 mg single-dose vials of lyophilized powder + 30 × 10 mL Sterile Water for Injection bottles + 30-day supply of disposable syringes/needles in the Injection Box (source: prescriberpoint.com IFU summary, 2026).
  • Research-chem listing: lyophilized vial (common sizes 5 mg / 10 mg seen — offerings UNVERIFIED).
  • What's needed alongside (factual, not instructions): diluent (Sterile Water for Injection in the Egrifta kit; bacteriostatic water in gray-market context), syringes.

Support reality

  • Pharma support: Thera Patient Support Program for Egrifta SV (copay assistance; phone 833-238-4372 per drugs.com); Egrifta ships through specialty pharmacies with injection training historically offered via the AXIS Center model.
  • Research-chem COA practices: Vendors typically post third-party COAs claiming ≥98–99% purity; quality unverified here.
  • Clinic support: Telehealth/wellness clinics prescribe compounded tesamorelin with provider oversight and lab monitoring per clinic protocols.

Regulatory & safety status

Plain statement: FDA-approved drug (Egrifta / Egrifta SV / Egrifta WR) — the only FDA-approved GHRH analog — indicated for reduction of excess abdominal/visceral fat in HIV-infected adults with lipodystrophy. NOT indicated for weight-loss management (weight-neutral per label) and long-term cardiovascular safety/benefit is not established (label limitation). All non-HIV, cosmetic, bodybuilding, and gray-market use is off-label/unapproved. WADA-prohibited at all times (S2.2.4, GHRH analogs). Label/community safety signals: injection-site reactions, flushing/warmth, fluid retention and carpal-tunnel-like symptoms, muscle pain, numbness, and blood-glucose elevation — monitor glucose, especially in diabetic/prediabetic users. Contraindications per label include active malignancy and pregnancy (standard GH-axis warnings — exact current label not re-read today; treat as UNVERIFIED detail).

Community verdict

Tesamorelin is the community's most credentialed GH secretagogue — real FDA approval, real Phase III fat-loss data — and its "visceral fat peptide" reputation is actively debated as a labeling artifact versus a genuine mechanistic edge over cheaper CJC-1295. The blocker is price: at ~$10k/month for Egrifta, nearly all community use is gray-market, which is exactly where the spam, quality questions, and off-label risk concentrate.

Image log

Open questions / UNVERIFIED

  • The "stable IGF-1 over 52 weeks without desensitization" claim (May 2026 creator video) — creator-cited studies, not verified against primary sources.
  • Community price range $13–$180 per 10 mg — single comment thread, unverified.
  • Molecular weight (~5,136 Da) and CAS (218949-48-5) — plausible, not verified today.
  • Whether tesamorelin meaningfully outperforms CJC-1295 for visceral fat — never tested head-to-head; community debate unresolved.
  • Egrifta WR (Mar 2025 formulation) pricing and availability — not collected.
  • Exact current label contraindications (active malignancy, pregnancy) — standard but not re-read from the current label today.

Not medical advice. This file is research documentation only; nothing here is a recommendation to use any compound.

Tesamorelin — box view
box view Original vendor page URL not recorded in research dossier
Tesamorelin — detail view
detail view Original vendor page URL not recorded in research dossier
Tesamorelin — hero view
hero view Original vendor page URL not recorded in research dossier
Tesamorelin — rear view
rear view Original vendor page URL not recorded in research dossier
Tesamorelin — side view
side view Original vendor page URL not recorded in research dossier

Sources